Posted by Michael Wonder on 25 Jul 2022
Applications for proposed first of a kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
25 July 2022 - Submission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EU.
Sandoz announced today that the US FDA has accepted its biologics license application for a proposed first of a kind biosimilar natalizumab, developed by Polpharma Biologics.
